No valid treatment for isolated myeloid sarcoma (IMS) has yet been established, and no thorough genetic examinations have been performed because of its low incidence and unique manner of development. We herein report a 34-year-old man with pancreatic IMS with t(8;21)/RUNX1-RUNX1T1 rearrangement. He was treated with high-dose cytarabine followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). This is the first report of pancreatic IMS with t(8;21). Positron emission tomography/computed tomography and genetic study are useful for the diagnosis, and allo-HSCT achieved complete remission in this patient.
Introduction
Myeloid sarcoma (MS) is a characteristic disease entity in myeloid neoplasms. In most MS cases, leukemic blasts in the peripheral blood and bone marrow (BM) are found at the diagnosis (1) . MS is recognized in approximately 5% of acute myeloid leukemia (AML) cases (2) . However, AML cells are not detected in the peripheral blood or BM of isolated MS (IMS) cases. Given that IMS is found in 25% of MS cases (1) , IMS is assumed to be present in 1% of AML cases.
MS, including IMS, consists of immature myeloid cells and may develop in lesions throughout the body. The skin, lymph node, testis and digestive tract are common sites of MS. IMS, which is not concomitant with leukemic blasts in the peripheral blood or BM, often lacks specific symptoms and is therefore difficult to diagnose properly. In many cases of IMS, it is difficult to access and obtain sufficient specimens for a diagnosis because of the anatomical sites of the tumors. Occasionally, a needle biopsy is clinically useful. However, needle biopsy samples are not adequate for immunochemistry and genetic analyses.
The low incidence, varied and non-specific clinical symptoms, difficulty in obtaining diagnostic specimens and variety of histological appearance of IMS make its diagnosis and treatment challenging (2, 3) . No valid treatment has been established, and how to treat the disease is a matter of concern in clinical hematology.
Case Report
A 34-year-old man complained of a 3-month history of upper abdominal pain. Abdominal echography and computed tomography (CT) images revealed a tumor in the pancreas. Thereafter, he was referred to our hospital (Kumamoto University Hospital, Kumamoto, Japan). The peripheral blood cell counts were all within normal ranges: white blood cell count 4.4×10 (A) (B) (C) creatinine were not markedly increased. Contrast-enhanced CT showed a 10×6-cm ischemic bulky tumor in the pancreas body and tail with a thickened greater omentum (Fig. 1A) . A tumor biopsy was performed with laparoscopy, and a few milliliters of turbid ascites was obtained ( Fig. 1B and C) . Cytologically, the tumor cells were immature leukemic blast-like cells with blue-gray cytoplasm and an indented nucleus with fine chromatin without adepithelial connections (Fig. 2 , May-Giemsa staining). A histopathological study revealed that the tumor cells were negative for lymphoid and epithelial markers, CD3, CD7, CD20, terminal deoxynucleotidyl transferase (TdT) and cytokeratin AE1/AE3. A flow cytometric analysis and immunohistochemical study revealed that the cells in ascites were positive for myeloid and monocyte antigens, CD4, CD15, CD33, CD34, CD56, CD68/Kp-1 and myeloperoxidase (MPO) (Fig. 2) . Therefore, the pancreatic tumor was diagnosed as MS. Positron emission tomography (PET)/CT showed that 18 F-fluorodeoxyglucose (FDG) was taken up only by the pancreatic tumor and thickened greater omentum (maximum standard uptake value [SUVmax]: 8.8). Leukemic blasts were not found in the BM by histological or cytological analyses. The patient was diagnosed with pancreatic IMS with invasion to the greater omemtum and ascites. He was treated with the AML regimen of idarubicin for three days and cytarabine for seven days.
The WT1 mRNA level in the peripheral blood increased to 1,000 copies/μgRNA at the diagnosis. The tumor cells obtained by a biopsy were not enough for a G-banding analysis. To predict the prognosis, fluorescence in situ hybridization (FISH) for RUNX1-RUNX1T1 rearrangement was additionally ordered based on the knowledge that such a rearrangement is sometimes found in MS cases. RUNX1-RUNX1T1 fusion signals were detected in 17.6% of the tumor cells by FISH using the Vysis LSI RUNX1/RUNX1T1 Dual Color Dual Fusion Probes (Abbott Molecular, Des Plaines, USA). In contrast, the fusion signal was not detected in BM cells at the diagnosis. The patient was ultimately diagnosed with pancreatic IMS with t(8;21) (q22;q22)/RUNX1-RUNX1T1 rearrangement. cKIT exon 8 and 17 mutations were not found by sequencing cDNA extracted from the tumor cells. Reverse transcription polymerase chain reaction (RT-PCR) revealed that RUNX1-RUNX1T1 fusion mRNA was detected in the tumor cells and the BM mononuclear cells (Fig. 3) . These data suggest the presence of a small number of leukemic cells or nonleukemic cells with the RUNX1-RUNX1T1 fusion gene in the BM.
The idarubicin and cytarabine regimen was followed by three cycles of high-dose cytarabine regimens. The WT1 mRNA level was reduced to 93 copies/μgRNA. In addition, PET/CT revealed no 18 F-FDG-positive lesion in the pancreas, and RT-PCR showed no RUNX1-RUNX1T1-positive cells in the BM. Therefore, we concluded that our patient had achieved complete remission (CR). He was treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an human leukocyte antigen (HLA)-matched unrelated donor with busulfan and cyclophosphamide as the conditioning regimen using cyclosporine and short-course methotrexate as graft-versus-host disease prophylaxis. He has been in CR for 1.5 years since the diagnosis (Fig. 4) . The RUNX1-RUNX1T1 fusion gene has not been detected by PCR, and the WT1 mRNA count has dropped below 50 copies/μgRNA (lower limit of normal) since HSCT.
Discussion
A number of different cytogenetic abnormalities in MS have been reported, but which ones are specific to MS is not known (1, 4) . Translocation (8;21) is a common cytogenetic abnormalities. Avni et al. reported that the rate of t(8;21) in MS patients ranged from 3.3% to 43% (5). MS with t(8;21) tends to develop orbitally or peri-orbitally (6). Only 13 cases of pancreatic MS cases, including the present case, have been reported since 1987 (Table) (7-16). Our case is believed to be a rare report of genetically confirmed pancreatic IMS with t(8;21)(q22;q22)/RUNX1-RUNX1T1 rearrangement. A genetic analysis by FISH is useful for the diagnosis of MS.
In our IMS case, only RT-PCR indicated the presence of cells harboring the RUNX1-RUNX1T1 gene in BM, which is similar to a previous report showing RUNX1-RUNX1T1 fusion mRNA in BM in a case of IMS (17) . IMS patients subsequently develop AML after an average of 10 months (18, 19) . It is possible that there are a small number of leukemic cells in the BM at the diagnosis of IMS, leading to AML. Therefore, IMS should be treated by systemic chemotherapy. There have been no large prospective studies on a suitable therapy for IMS because of its low incidence. The efficacy of cytarabine-based regimens has been reported in small numbers of patients (20) (21) (22) . In AML with t(8;21), MS is assumed to be a poor prognostic factor; the median survival time of patients with AML with t(8;21) is 59.5 months, compared to 5.4 months for patients with AML with t(8;21) and MS (23) . Among 12 patients with pancreatic MS, CR of 2 years' duration was achieved in 2 patients treated with chemotherapy combined with surgical resection or HSCT (Cases 2 and 7 in Table) . Given the poor prognosis of MS with t(8;21), the previous reports of pancreatic MS, and the existence of disseminative disease, we planned allo-HSCT for our case. Allo-HSCT in addition to systemic chemotherapy may improve the prognosis of patients with IMS. The retrospective study by Antic et al. revealed that the 5-year overall survival (OS) of 12 IMS patients was 25%, and survival for >50 months was found in 2 of 3 patients treated with HSCT but only 1 of 9 patients without HSCT (24). Chevallier et al. reported that, in 30 patients with IMS who received allo-HSCT, the 5-year OS, leukemia-free survival rate and nonerelapse mortality were 33%, 30% and 17%, respectively. In addition, the authors pointed out that having achieved CR at allo-HSCT and lacking a poor prognostic karyotype were indicators of a good prognosis (25) . Lazzarotto et al. analyzed the clinical outcome of 48 MS patients, including 9 IMS patients, and similarly reported that allo-HSCT after intensive chemotherapy improved the prognosis (OS probability at 5 years for the whole population and for the 22 MS patients who received allo-HSCT: 33% and 53%, respectively). In addition, having achieved CR at allo-HSCT influenced a better prognosis (26) . Allo-HSCT is assumed to improve the prognosis of patients with IMS. Allo-HSCT may be considered the primary treatment option for IMS, although the findings from these retrospective studies may include some selection bias. In addition, the evaluation of the treatment response and cytogenetic information in IMS cases are important.
MS is an extramedullary neoplastic tumor of immature myeloid cells, with various types and numbers of inflammatory cells. There are no known highly sensitive and specific antigens for the diagnosis of MS cells. It is usually difficult to obtain enough specimens for genetic examinations because of the site and size of IMS. However, genetic information is necessary to clarify the origin of IMS and plan treatment. Therefore, we performed a laparoscopic biopsy of the pancreas. Immunophenotyping with a histological analysis, flow cytometry and a genetic analysis of the biopsy samples resulted in a proper diagnosis of IMS. There is no sensitive method for assessing deep CR, such as flow cytometry or RT-PCR, in IMS. PET/CT is effective for the evaluation of the residual tumor and treatment response. PET/CT can detect MS more sensitively than standard CT and magnetic resonance imaging (27, 28) . MS can develop at any site in the body, and PET/CT is useful for screening for MS, finding a biopsy site, and evaluating the treatment response (28, 29) . In the present case, 18 F-FDG PET/CT were utilized for the assessment of the treatment response.
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